



## **Can-Fite BioPharma announces its intention to register ADRs in the US**

**Petah Tikva, Israel, July 3 2012: Can-Fite BioPharma (TASE: CFBI)** announced today that the Company is planning to register its shares for trading in the US via ADRs (American Depository Receipts), and subject to filing and receiving all the needed approval from the US Securities and Exchange Commission. The Company will act in order to register a level II ADRs and to list it in one of the main US stock markets.

In addition, the company further announced that following the completion of treatment of the first 100 patients in the phase II/III study of CF101 for the treatment of psoriasis, an interim analysis recommendation by an independent data monitoring committee (DMC) is expected to be released in the third quarter this year.

Furthermore, the Company plans to release in the coming months the results of its Rheumatoid Arthritis Phase IIb trial with CF101. This study will include 80 patients. Patient eligibility is based on the presence of the A3 adenosine receptor bio-marker, tested in the peripheral blood mononuclear cells (PBMNC) of the patients prior to treatment.

### **About Can-Fite BioPharma Ltd.**

Can-Fite BioPharma Ltd is a public company, trading on the Tel Aviv Stock Exchange. The company, which commenced business activity on 2000, was founded by Prof Pnina Fishman, researcher in the Rabin Medical Center, and Dr Ilan Cohen, patent attorney and senior partner at Reinhold Cohen Patent Attorneys. Prof Fishman serves as CEO of the company. The company was founded on the basis of Prof Fishman's scientific findings, and is focused on the development of small molecule drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in advanced clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite recently licensed its activity in the ophthalmic field to OphthaliX Inc.

**Contact:**

Pnina Fishman, Chief Executive Officer

Tel: +972-3-9241114

Email: [pnina@canfite.com](mailto:pnina@canfite.com)